Detalles de la búsqueda
1.
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR-T and TCR-T Cellular Therapies Development.
Clin Pharmacol Ther
; 115(2): 188-200, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37983584
2.
Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular Product.
J Pharm Sci
; 2024 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38768755
3.
Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodies.
Anal Biochem
; 441(2): 174-9, 2013 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23886888
4.
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective.
Clin Pharmacol Ther
; 114(3): 530-557, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37393588
5.
Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development.
AAPS J
; 25(4): 55, 2023 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37266912
6.
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies.
Anal Bioanal Chem
; 402(3): 1229-39, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22130720
7.
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.
Front Immunol
; 11: 1301, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32695107
8.
Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.
J Nucl Med
; 59(3): 529-535, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29025984
9.
Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro.
Chem Biol
; 13(5): 549-56, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16720276
10.
How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective.
AAPS J
; 19(6): 1587-1592, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28971356
11.
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins.
CPT Pharmacometrics Syst Pharmacol
; 8(11): 773-776, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31529677
12.
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
Clin Cancer Res
; 17(2): 363-71, 2011 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21224368
13.
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
MAbs
; 3(1): 38-48, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21099371
14.
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.
MAbs
; 2(2): 199-208, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20190562
Resultados
1 -
14
de 14
1
Próxima >
>>